Where are the next Immuno-Oncology breakthroughs coming from?
Barcelona: What makes a great scientist is not accepting conventional wisdom or dogma but instead thinking differently, pursuing what data generated truly means, and asking if we can do things differently as a result?
Current success in immuno-oncology new product development has been built on basic research done twenty and thirty years ago, when many didn’t believe in leveraging the power of the immune system therapeutically.
At the ongoing European Association for Cancer Research (EACR) “Defense is the Best Attack” meeting in Barcelona this week, many experts in the IO field are sharing novel findings on what may lead to future insights.
What were some of the key take-homes?
Subscribers can read our notes from some of the presentations that stood out at the meeting.
If you’re not yet a BSB subscriber and are interested in learning from our science and clinical commentary/analysis then come join a growing band of enthusiastic readers!
To learn more from our latest conference coverage and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
This content is restricted to subscribers